modafinil has been researched along with ADDH in 51 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 8.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| " In this study, we report the case of a patient with adult ADHD with co-morbid amphetamine abuse who was treated successfully with the non-stimulant alertness-promoting drug modafinil." | 7.75 | Modafinil treatment of amphetamine abuse in adult ADHD. ( Bitsios, P; Mann, N, 2009) |
| "For more than two decades psychiatrists have known about and have promoted modafinil, a very promising stimulant that boosts wakefulness in cases of narcolepsy and also enhances cognitive functions." | 4.86 | [Modafinil in psychiatric disorders: the promising state reconsidered]. ( Docx, L; Dom, G; Joos, L; Sabbe, BG; Schmaal, L, 2010) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 4.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| " In this study, we report the case of a patient with adult ADHD with co-morbid amphetamine abuse who was treated successfully with the non-stimulant alertness-promoting drug modafinil." | 3.75 | Modafinil treatment of amphetamine abuse in adult ADHD. ( Bitsios, P; Mann, N, 2009) |
| "Modafinil was reasonably tolerated but did not demonstrate a benefit on ADHD symptoms in adults." | 2.79 | A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. ( Adler, LA; Arnold, VK; Earl, CQ; Feifel, D; Yang, R, 2014) |
| "Modafinil is a centrally acting agent that is structurally and pharmacologically different from stimulants such as amphetamine and methylphenidate." | 2.74 | A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. ( Akhondzadeh, S; Ghoreishi, A; Kahbazi, M; Kamalipour, A; Mohammadi, MR; Rahiminejad, F, 2009) |
| "Modafinil was generally well tolerated." | 2.72 | Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. ( Biederman, J; Earl, CQ; Greenhill, LL; Jiang, JG; Lopez, FA; Sedillo, A; Swanson, JM, 2006) |
| "Modafinil was well tolerated and reduced ADHD symptoms at school and home compared with placebo." | 2.72 | A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. ( Biederman, J; Boellner, SW; Earl, CQ; Greenhill, LL; Jiang, JG; Rugino, TA; Sangal, RB; Swanson, JM, 2006) |
| "This randomized, double-blind, placebo-controlled study assessed the efficacy and tolerability of several modafinil dosing regimens in children with attention-deficit/hyperactivity disorder (ADHD) to determine whether modafinil can be given once daily in pediatric ADHD." | 2.72 | A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. ( Biederman, J; Boellner, SW; Earl, CQ; Lopez, FA; Swanson, JM; Wigal, SB, 2006) |
| " Limitations of the study include open-label dosing and lack of a placebo control." | 2.72 | Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. ( Arora, S; Boellner, SW; Earl, CQ, 2006) |
| "Treatment with modafinil also significantly reduced subscale scores for inattention and hyperactivity-impulsivity on both School and Home Versions compared with placebo." | 2.71 | Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. ( Biederman, J; Boellner, SW; Earl, CQ; Greenhill, L; Jiang, J; Kratochvil, CJ; Swanson, JM; Wigal, SB, 2005) |
| "To examine the effect of once-daily dosing of modafinil, a stimulant that has a long duration of action, on clinical features of attention-deficit/hyperactivity disorder (ADHD) in children." | 2.70 | Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. ( Copley, TC; Rugino, TA, 2001) |
| "Modafinil did not cause a clinically significant increase of heart rate, systolic blood pressure, and diastolic blood pressure." | 2.55 | Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. ( Han, C; Jun, TY; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM, 2017) |
| " Side effects of stimulants are generally mild, short lived, and responsive to adjustments in dosage or timing." | 2.44 | Changes and challenges: managing ADHD in a fast-paced world. ( Bukstein, OG; Crismon, ML; Manos, MJ; Tom-Revzon, C, 2007) |
| "Modafinil (Provigil) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults." | 2.43 | A review of the use of modafinil for attention-deficit hyperactivity disorder. ( Turner, D, 2006) |
| "Modafinil is a novel wake-promoting agent that has U." | 2.43 | A systematic review of modafinil: Potential clinical uses and mechanisms of action. ( Ballon, JS; Feifel, D, 2006) |
| " Human mesenchymal stem cells (hMSCs) were incubated with a therapeutic plasma dosage of modafinil, atomoxetine and guanfacine." | 1.72 | Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration. ( Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L, 2022) |
| "Modafinil is a wakefulness-promoting agent that is known to be used off-label as a cognitive enhancer and for the treatment of attention deficit hyperactivity disorder (ADHD)." | 1.62 | Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder. ( Flavell, J, 2021) |
| "Modafinil was associated with greater improvements on the CGI-I and improved CPRS-R:S subscale scores in inattentive and combined subtypes." | 1.35 | Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. ( Biederman, J; Pliszka, SR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (52.94) | 29.6817 |
| 2010's | 18 (35.29) | 24.3611 |
| 2020's | 6 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Wagener, N | 1 |
| Lehmann, W | 1 |
| Weiser, L | 1 |
| Jäckle, K | 1 |
| Di Fazio, P | 1 |
| Schilling, AF | 1 |
| Böker, KO | 1 |
| Bang Madsen, K | 1 |
| Robakis, TK | 1 |
| Liu, X | 1 |
| Momen, N | 1 |
| Larsson, H | 1 |
| Dreier, JW | 1 |
| Kildegaard, H | 1 |
| Groth, JB | 1 |
| Newcorn, JH | 1 |
| Hove Thomsen, P | 1 |
| Munk-Olsen, T | 1 |
| Bergink, V | 1 |
| Fukumoto, S | 1 |
| Imanari, E | 1 |
| Tomari, S | 1 |
| Higashi, T | 1 |
| Kosaka, H | 1 |
| Flavell, J | 1 |
| Elliott, J | 1 |
| Johnston, A | 1 |
| Husereau, D | 1 |
| Kelly, SE | 1 |
| Eagles, C | 1 |
| Charach, A | 1 |
| Hsieh, SC | 1 |
| Bai, Z | 1 |
| Hossain, A | 1 |
| Skidmore, B | 1 |
| Tsakonas, E | 1 |
| Chojecki, D | 1 |
| Mamdani, M | 1 |
| Wells, GA | 1 |
| Thomas, EM | 1 |
| Freeman, TP | 1 |
| Poplutz, P | 1 |
| Howden, K | 1 |
| Hindocha, C | 1 |
| Bloomfield, M | 1 |
| Kamboj, SK | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| King, SA | 1 |
| Casavant, MJ | 1 |
| Spiller, HA | 1 |
| Hodges, NL | 1 |
| Chounthirath, T | 1 |
| Smith, GA | 1 |
| Stuhec, M | 1 |
| Lukić, P | 1 |
| Locatelli, I | 1 |
| Fowler, E | 1 |
| Maderal, A | 1 |
| Yosipovitch, G | 1 |
| Wilms, W | 1 |
| Woźniak-Karczewska, M | 1 |
| Corvini, PF | 1 |
| Chrzanowski, Ł | 1 |
| Warrer, P | 1 |
| Aagaard, L | 1 |
| Hansen, EH | 1 |
| Lecendreux, M | 1 |
| Lavault, S | 1 |
| Lopez, R | 1 |
| Inocente, CO | 1 |
| Konofal, E | 1 |
| Cortese, S | 1 |
| Franco, P | 1 |
| Arnulf, I | 1 |
| Dauvilliers, Y | 1 |
| Sahakian, BJ | 4 |
| Morein-Zamir, S | 1 |
| Buoli, M | 1 |
| Serati, M | 1 |
| Cahn, W | 1 |
| Savulich, G | 1 |
| Piercy, T | 1 |
| Brühl, AB | 1 |
| Fox, C | 1 |
| Suckling, J | 1 |
| Rowe, JB | 1 |
| O'Brien, JT | 1 |
| Wang, SM | 1 |
| Han, C | 1 |
| Lee, SJ | 1 |
| Jun, TY | 1 |
| Patkar, AA | 1 |
| Masand, PS | 1 |
| Pae, CU | 1 |
| Mann, N | 1 |
| Bitsios, P | 1 |
| Kahbazi, M | 2 |
| Ghoreishi, A | 1 |
| Rahiminejad, F | 1 |
| Mohammadi, MR | 2 |
| Kamalipour, A | 1 |
| Akhondzadeh, S | 2 |
| Lang, HC | 1 |
| Scheffler, RM | 1 |
| Hu, TW | 1 |
| Joos, L | 1 |
| Docx, L | 1 |
| Schmaal, L | 1 |
| Sabbe, BG | 1 |
| Dom, G | 1 |
| McDonnell, MA | 1 |
| Moffett, C | 1 |
| Franke, AG | 1 |
| Konrad, A | 1 |
| Lieb, K | 1 |
| Huss, M | 1 |
| Howland, RH | 1 |
| Goez, HR | 1 |
| Scott, O | 1 |
| Nevo, N | 1 |
| Bennett-Back, O | 1 |
| Zelnik, N | 1 |
| Arnold, VK | 1 |
| Feifel, D | 2 |
| Earl, CQ | 6 |
| Yang, R | 1 |
| Adler, LA | 1 |
| Schweitzer, JB | 1 |
| Holcomb, HH | 1 |
| Pliszka, SR | 2 |
| Rugino, TA | 3 |
| Samsock, TC | 1 |
| Turner, DC | 2 |
| Clark, L | 2 |
| Pomarol-Clotet, E | 1 |
| McKenna, P | 1 |
| Robbins, TW | 3 |
| Dowson, J | 1 |
| Waxmonsky, JG | 1 |
| Biederman, J | 7 |
| Swanson, JM | 4 |
| Wigal, SB | 2 |
| Kratochvil, CJ | 1 |
| Boellner, SW | 4 |
| Jiang, J | 1 |
| Greenhill, L | 1 |
| Greenhill, LL | 2 |
| Lopez, FA | 2 |
| Sedillo, A | 1 |
| Jiang, JG | 2 |
| Arnsten, AF | 1 |
| Faraone, SV | 1 |
| Doyle, AE | 1 |
| Spencer, TJ | 1 |
| Wilens, TE | 1 |
| Weiss, MD | 1 |
| Safren, SA | 1 |
| Culpepper, L | 1 |
| Sangal, RB | 1 |
| Turner, D | 1 |
| Ballon, JS | 1 |
| Lindsay, SE | 1 |
| Gudelsky, GA | 1 |
| Heaton, PC | 1 |
| Arora, S | 1 |
| Eagle, DM | 1 |
| Tufft, MR | 1 |
| Goodchild, HL | 1 |
| Kruszewski, SP | 1 |
| Klotz, SG | 1 |
| Valentino, RM | 1 |
| Foldvary-Schaefer, N | 1 |
| Amiri, S | 1 |
| Mohammadi, M | 1 |
| Nouroozinejad, GH | 1 |
| Zhu, HJ | 1 |
| Wang, JS | 1 |
| Donovan, JL | 1 |
| Jiang, Y | 1 |
| Gibson, BB | 1 |
| DeVane, CL | 1 |
| Markowitz, JS | 1 |
| Manos, MJ | 1 |
| Tom-Revzon, C | 1 |
| Bukstein, OG | 1 |
| Crismon, ML | 1 |
| Taylor, FB | 1 |
| Russo, J | 1 |
| Copley, TC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls[NCT02051153] | 64 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for modafinil and ADDH
| Article | Year |
|---|---|
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes | 2020 |
Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2019 |
Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Environmental Pollutants; Humans; Memory; Meth | 2019 |
Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
Topics: Adrenergic alpha-Agonists; Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder wi | 2016 |
Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous Sys | 2017 |
[Modafinil in psychiatric disorders: the promising state reconsidered].
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2010 |
[Stimulant and non-stimulant medication in current and future therapy for ADHD].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Defi | 2012 |
Drugs under investigation for attention-deficit hyperactivity disorder.
Topics: Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2002 |
Non-stimulant treatment of attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Antidepressive Agents, Tricyclic; Atomoxetine Hydr | 2003 |
Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2005 |
A review of the use of modafinil for attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Humans; Modafinil | 2006 |
A systematic review of modafinil: Potential clinical uses and mechanisms of action.
Topics: Animals; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; | 2006 |
Use of modafinil for the treatment of attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Humans; Modafinil | 2006 |
Modafinil in the treatment of excessive daytime sleepiness.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2007 |
Changes and challenges: managing ADHD in a fast-paced world.
Topics: Algorithms; Antihypertensive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2007 |
15 trials available for modafinil and ADDH
| Article | Year |
|---|---|
Stimulating meditation: a pre-registered randomised controlled experiment combining a single dose of the cognitive enhancer, modafinil, with brief mindfulness training.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Combined Modality Thera | 2021 |
A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous Sys | 2009 |
Using the test of variables of attention to determine the effectiveness of modafinil in children with attention-deficit hyperactivity disorder (ADHD): a prospective methylphenidate-controlled trial.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Con | 2012 |
A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD.
Topics: Adult; Aged; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Dose-Response Rela | 2014 |
Modafinil in children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous Sys | 2003 |
Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
Topics: Adult; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Benzhydryl Co | 2004 |
Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Blood Pressur | 2004 |
Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous Sys | 2005 |
Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Body Weight; Centra | 2006 |
A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous Sys | 2006 |
A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Body W | 2006 |
Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Child; Double-Blind | 2006 |
Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Child; Diagnostic a | 2008 |
Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nerv | 2000 |
Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous Sys | 2001 |
21 other studies available for modafinil and ADDH
| Article | Year |
|---|---|
Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Differentiatio | 2022 |
In utero exposure to ADHD medication and long-term offspring outcomes.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child, Preschool; Clonidine; Coh | 2023 |
[Psychostimulants: An Overview].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Lisdexamfe | 2023 |
Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2021 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Pediatric ADHD Medication Exposures Reported to US Poison Control Centers.
Topics: Adolescent; Age Distribution; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder wit | 2018 |
Treatment-induced Delusions of Infestation Associated with Increased Brain Dopamine Levels.
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Brain; Deep Brain Stimulation; Delusional Paras | 2019 |
Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Benzhydryl Comp | 2014 |
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Control Studie | 2015 |
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
Topics: Alzheimer Disease; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Cholinestera | 2015 |
Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Cognition; Cognition Disorders; | 2017 |
Modafinil treatment of amphetamine abuse in adult ADHD.
Topics: Adult; Amphetamine-Related Disorders; Attention; Attention Deficit Disorder with Hyperactivity; Benz | 2009 |
The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Cent | 2010 |
Coming into focus. Pharmacologic treatment for ADHD.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidepressive Agents; Attention Deficit Disorder with Hyperac | 2010 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2012 |
New developments in the treatment of ADHD.
Topics: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2006 |
Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-Agonists; Adult; Attention Deficit Disorder | 2006 |
Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Benzhydryl Compounds; Cent | 2007 |
Modafinil: mischaracterization.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2007 |
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Topics: Adenosine Triphosphate; Amphetamine; Animals; Atomoxetine Hydrochloride; ATP Binding Cassette Transp | 2008 |
Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Centra | 2008 |